Priority Date: 20.03.12 (EP 20120382101)

NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ss2 ADRENERGIC RECEPTOR.

  • Application ID: EP13719407
  • Status: EXAMINATION IN PROGRESS

Applicant

Technology company logo small
Technology Company

Attorney

no operation time available
1141.11
Headquarter in London and 4 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

Specialization

This EP application has the IPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 190 others are specialized in this combination either. For a similar patent, they might be a good choice.

Timeline

  • 20.03.2012 - Priority Date (EP 20120382101)
  • 26.09.2013 - Publication A1 (WO2013139712)
  • 28.01.2015 - Publication A1 (EP2828242)

IPC Classification